Our Science
To create a medicine
to treat diseases

of the nervous system
Our Mission
To improve people’s quality
of life
through innovative,
sustainable and effective pain relief

Therapeutic focus » Our Science

PN6047 – a unique mode of action

PharmNovo’s mission is to discover new, safe, and effective drugs to help patients suffering from neuropathic pain. We combine innovative chemistry and bioscience to discover new treatments for neuropathic pain and other diseases of the nervous system.

Our drug candidate PN6047 is an agonist, a  drug that binds to and activates a specific receptor. It is a potent, carefully developed, small molecule that selectively activates the delta (δ) opioid receptor (DOR).

PN6047 does not, like conventional opioids, affect the mu (μ) opioid receptor, which is known to provide adequate relief for acute pain, but also causes addiction and severe side effects, such as  respiratory depression, abuse potential, itching and constipation.

Activating the delta receptor does not provide acute pain relief - but it produces an excellent reversal of neuropathic pain in animal models.

The approach of  activating the delta receptor is entirely new. The underlying concept is to specifically activate the beneficial parts of the system while avoiding the type of activation that results in unwanted side effects.

Latest news

View all
June 5, 2024

PharmNovo presenting at the Global Forum

On May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.

Read more
March 21, 2024

Positive final Phase I results

The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.

Read more
March 10, 2024

Meet Bengt von Mentzer, founder and Chief scientific advisor

Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.

Read more
January 30, 2024

NIDA funds studies

The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.

Read more